Increased Numb protein expression predicts poor clinical outcomes in esophageal squamous cell carcinoma patients

Cancer Biol Ther. 2018 Jan 2;19(1):34-41. doi: 10.1080/15384047.2016.1276131. Epub 2017 Dec 18.

Abstract

Numb is a protein whose asymmetric segregation during cell division determines cell fate and has numerous functions relevant to multiple fields of study, including developmental neurobiology and cancer biology. Little is known about the role of Numb in esophageal squamous cell carcinoma (ESCC), the predominant histological esophageal carcinoma in Asian populations. In this study, we focused on the expression and biologic functions of Numb in the context of ESCC. From analysis of tissue microarrays with 212 patients, it was found that Numb was significantly upregulated in ESCC tissues compared with corresponding non-cancerous tissues. Kaplan-Meier survival analysis suggests that higher expression of Numb was significantly associated with a high tumor recurrence (p = 0.015) and poor overall post-surgical survival (p = 0.016). Using multiple Cox regression, the expression of Numb was determined to be an independent predictor of poor prognosis. When siRNA was used to knockdown Numb in ESCC cell lines, there was a consistent increase in caspase-3 dependent apoptosis and inhibition of cellular proliferation, as well as downregulation of expression of the cancer stem cell markers Oct-4, SOX-2 and Nanog. In addition, downregulated Numb expression was not significantly associated with the migration of ESCC cells. These results indicate that Numb acts as an oncoprotein and has potential as a novel prognostic biomarker and therapeutic target in ESCC patients.

Keywords: Apoptosis; ESCC; Numb protein; cancer stem cell; esophageal squamous cell carcinoma; prognosis; proliferation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Proliferation / genetics
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • Down-Regulation
  • Esophageal Neoplasms / mortality
  • Esophageal Neoplasms / pathology*
  • Esophageal Neoplasms / therapy
  • Esophageal Squamous Cell Carcinoma / mortality
  • Esophageal Squamous Cell Carcinoma / pathology*
  • Esophageal Squamous Cell Carcinoma / therapy
  • Esophagectomy
  • Esophagus / pathology
  • Female
  • Gene Knockdown Techniques
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism*
  • Middle Aged
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology*
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism*
  • Oncogene Proteins / genetics
  • Oncogene Proteins / metabolism
  • Prognosis
  • RNA, Small Interfering / metabolism
  • Tissue Array Analysis
  • Up-Regulation

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Membrane Proteins
  • Nerve Tissue Proteins
  • NUMB protein, human
  • Oncogene Proteins
  • RNA, Small Interfering
  • Cisplatin

Grants and funding

This study is supported by National Natural Science Foundation of China under Grant No. 81171125 and 81572391 to C. Cheng, Science and Technology Planning Project of Guangdong Province under Grant No. 2016A020215050 to C. Cheng, and the Research and Development Program of Sun Yat-sen University under Grant 10YKPY09 to C. Cheng.